Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.

Viglietta, Vissia

Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. [electronic resource] - Investigational new drugs 10 2020 - 1463-1471 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1573-0646

10.1007/s10637-020-00918-1 doi


Adult
Antineoplastic Agents--administration & dosage
Cisplatin--administration & dosage
Double-Blind Method
Female
Healthy Volunteers
Hearing Loss--chemically induced
Humans
Injection, Intratympanic
Male
Middle Aged
Neoplasms--drug therapy
Thiosulfates--administration & dosage
Young Adult